PYX-201
- Generic Name
- PYX-201
- Drug Type
- Biotech
- Background
PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin.
Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Pyxis Oncology, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT06795412
- Locations
- 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
Study of PYX-201 in Solid Tumors
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Pyxis Oncology, Inc
- Target Recruit Count
- 120
- Registration Number
- NCT05720117
- Locations
- 🇺🇸
SCRI - HealthOne Denver, Denver, Colorado, United States
🇺🇸University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath